Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Cytomegalovirus infection in pregnancy

Jeanne S Sheffield, MD
Suresh B Boppana, MD
Section Editors
Louise Wilkins-Haug, MD, PhD
Martin S Hirsch, MD
Deputy Editor
Vanessa A Barss, MD, FACOG


Cytomegalovirus (CMV) is a ubiquitous DNA herpesvirus. As with other herpesviruses, it becomes latent after a primary infection but can reactivate with renewed viral shedding. Shedding can occur from multiple sites and for prolonged periods of time. Women can also become infected with a different viral strain.

CMV is the most common congenital viral infection, with birth prevalence of 0.48 to 1.3 percent in recent decades [1-4]. Congenital infection may be asymptomatic or symptomatic; symptomatic disease can be severe and life-threatening. Both asymptomatic and symptomatic newborns are at risk of developing long-term neurodevelopmental morbidity, particularly deafness.

This topic will discuss issues specific to CMV in pregnant and breastfeeding women. General issues related to CMV infection and CMV infections in other populations are reviewed separately. (See "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults" and "Acquired cytomegalovirus infection in children" and "Congenital cytomegalovirus infection: Clinical features and diagnosis".)


Routes of transmission — Maternal acquisition of CMV infection can occur via multiple routes, including close nonsexual contact (including household and occupational exposure [especially contact with young children]), sexual exposure, transfusion, and organ transplant. CMV has been cultured from multiple body fluids, including urine, saliva, blood, nasopharyngeal secretions, tears, cervical and vaginal secretions, semen, and breast milk. Transmission from respiratory droplets or aerosolized droplets is unlikely [5]. (See "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Transmission'.)

Seroprevalence — CMV infection is common: An epidemiologic study in the United States demonstrated seropositivity in approximately 58 percent of young women aged 15 to 44 years [3]. Seroprevalence increases with age, ranging from 50 to 100 percent, and varies by geographic residence, ethnicity, and socioeconomic factors [1-3]. The following characteristics are predictive of positive CMV serology:


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Feb 2017. | This topic last updated: Fri Mar 17 00:00:00 GMT 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17:253.
  2. Ornoy A, Diav-Citrin O. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. Reprod Toxicol 2006; 21:399.
  3. Staras SA, Dollard SC, Radford KW, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006; 43:1143.
  4. Mussi-Pinhata MM, Yamamoto AY, Moura Brito RM, et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis 2009; 49:522.
  5. Davis ML, King CC, Kourtis AP. Cytomegalovirus infection in pregnancy. Birth Defects Research 2017; 109:336.
  6. Fowler KB, Pass RF. Sexually transmitted diseases in mothers of neonates with congenital cytomegalovirus infection. J Infect Dis 1991; 164:259.
  7. Pass RF, Hutto C, Lyon MD, Cloud G. Increased rate of cytomegalovirus infection among day care center workers. Pediatr Infect Dis J 1990; 9:465.
  8. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003; 289:1008.
  9. Gratacap-Cavallier B, Bosson JL, Morand P, et al. Cytomegalovirus seroprevalence in French pregnant women: parity and place of birth as major predictive factors. Eur J Epidemiol 1998; 14:147.
  10. Hyde TB, Schmid DS, Cannon MJ. Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol 2010; 20:311.
  11. Nigro G, Anceschi MM, Cosmi EV, Congenital Cytomegalic Disease Collaborating Group. Clinical manifestations and abnormal laboratory findings in pregnant women with primary cytomegalovirus infection. BJOG 2003; 110:572.
  12. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5703a2.htm (Accessed on October 21, 2016).
  13. Eggers M, Bäder U, Enders G. Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy. J Med Virol 2000; 60:324.
  14. Lazzarotto T, Ripalti A, Bergamini G, et al. Development of a new cytomegalovirus (CMV) immunoglobulin M (IgM) immunoblot for detection of CMV-specific IgM. J Clin Microbiol 1998; 36:3337.
  15. Grangeot-Keros L, Mayaux MJ, Lebon P, et al. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. J Infect Dis 1997; 175:944.
  16. Leruez-Ville M, Sellier Y, Salomon LJ, et al. Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy: a retrospective cohort. Clin Infect Dis 2013; 56:1428.
  17. Kanengisser-Pines B, Hazan Y, Pines G, Appelman Z. High cytomegalovirus IgG avidity is a reliable indicator of past infection in patients with positive IgM detected during the first trimester of pregnancy. J Perinat Med 2009; 37:15.
  18. Revello MG, Genini E, Gorini G, et al. Comparative evaluation of eight commercial human cytomegalovirus IgG avidity assays. J Clin Virol 2010; 48:255.
  19. Lazzarotto T, Guerra B, Gabrielli L, et al. Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. Clin Microbiol Infect 2011; 17:1285.
  20. Lazzarotto T, Guerra B, Lanari M, et al. New advances in the diagnosis of congenital cytomegalovirus infection. J Clin Virol 2008; 41:192.
  21. Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis 2011; 52:e11.
  22. Society for Maternal-Fetal Medicine (SMFM), Hughes BL, Gyamfi-Bannerman C. Diagnosis and antenatal management of congenital cytomegalovirus infection. Am J Obstet Gynecol 2016; 214:B5.
  23. Picone O, Grangeot-Keros L, Senat M, et al. Cytomegalovirus non-primary infection during pregnancy. Can serology help with diagnosis? J Matern Fetal Neonatal Med 2017; 30:224.
  24. Picone O, Vauloup-Fellous C, Cordier AG, et al. A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome. Prenat Diagn 2013; 33:751.
  25. Gabrielli L, Bonasoni MP, Lazzarotto T, et al. Histological findings in foetuses congenitally infected by cytomegalovirus. J Clin Virol 2009; 46 Suppl 4:S16.
  26. Stagno S, Whitley RJ. Herpesvirus infections of pregnancy. Part I: Cytomegalovirus and Epstein-Barr virus infections. N Engl J Med 1985; 313:1270.
  27. Boppana SB, Fowler KB, Britt WJ, et al. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 1999; 104:55.
  28. Townsend CL, Forsgren M, Ahlfors K, et al. Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin Infect Dis 2013; 56:1232.
  29. Ross SA, Fowler KB, Ashrith G, et al. Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J Pediatr 2006; 148:332.
  30. Raynor BD. Cytomegalovirus infection in pregnancy. Semin Perinatol 1993; 17:394.
  31. Hamprecht K, Maschmann J, Vochem M, et al. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 2001; 357:513.
  32. Ross SA, Novak Z, Pati S, et al. Mixed infection and strain diversity in congenital cytomegalovirus infection. J Infect Dis 2011; 204:1003.
  33. Fowler KB, Stagno S, Pass RF, et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992; 326:663.
  34. Mwaanza N, Chilukutu L, Tembo J, et al. High rates of congenital cytomegalovirus infection linked with maternal HIV infection among neonatal admissions at a large referral center in sub-Saharan Africa. Clin Infect Dis 2014; 58:728.
  35. Manicklal S, van Niekerk AM, Kroon SM, et al. Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa. Clin Infect Dis 2014; 58:1467.
  36. Ellington SR, Clarke KE, Kourtis AP. Cytomegalovirus Infection in Human Immunodeficiency Virus (HIV)-Exposed and HIV-Infected Infants: A Systematic Review. J Infect Dis 2016; 213:891.
  37. Rodrigues S, Gonçalves D, Taipa R, Rodrigues Mdo C. Nonprimary Cytomegalovirus Fetal Infection. Rev Bras Ginecol Obstet 2016; 38:196.
  38. Zalel Y, Gilboa Y, Berkenshtat M, et al. Secondary cytomegalovirus infection can cause severe fetal sequelae despite maternal preconceptional immunity. Ultrasound Obstet Gynecol 2008; 31:417.
  39. Gaytant MA, Rours GI, Steegers EA, et al. Congenital cytomegalovirus infection after recurrent infection: case reports and review of the literature. Eur J Pediatr 2003; 162:248.
  40. Istas AS, Demmler GJ, Dobbins JG, Stewart JA. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis 1995; 20:665.
  41. Stagno S, Britt W. Cytomegalovirus infections. In: Infectious Diseases of the Fetus and Newborn Infant, 6th ed, Remington JS, Klein JO, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.739.
  42. Manicklal S, Emery VC, Lazzarotto T, et al. The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev 2013; 26:86.
  43. Enders G, Daiminger A, Bäder U, et al. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 2011; 52:244.
  44. Fowler KB, McCollister FP, Dahle AJ, et al. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 1997; 130:624.
  45. Pereira L, Petitt M, Fong A, et al. Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection. J Infect Dis 2014; 209:1573.
  46. Iwasenko JM, Howard J, Arbuckle S, et al. Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. J Infect Dis 2011; 203:1526.
  47. Guerra B, Lazzarotto T, Quarta S, et al. Prenatal diagnosis of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol 2000; 183:476.
  48. Azam AZ, Vial Y, Fawer CL, et al. Prenatal diagnosis of congenital cytomegalovirus infection. Obstet Gynecol 2001; 97:443.
  49. Liesnard C, Donner C, Brancart F, et al. Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk. Obstet Gynecol 2000; 95:881.
  50. Bodéus M, Hubinont C, Bernard P, et al. Prenatal diagnosis of human cytomegalovirus by culture and polymerase chain reaction: 98 pregnancies leading to congenital infection. Prenat Diagn 1999; 19:314.
  51. Revello MG, Furione M, Zavattoni M, et al. Human cytomegalovirus (HCMV) DNAemia in the mother at amniocentesis as a risk factor for iatrogenic HCMV infection of the fetus. J Infect Dis 2008; 197:593.
  52. Vauloup-Fellous C, Picone O, Cordier AG, et al. Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital. J Clin Virol 2009; 46 Suppl 4:S49.
  53. La Torre R, Nigro G, Mazzocco M, et al. Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. Clin Infect Dis 2006; 43:994.
  54. Simonazzi G, Guerra B, Bonasoni P, et al. Fetal cerebral periventricular halo at midgestation: an ultrasound finding suggestive of fetal cytomegalovirus infection. Am J Obstet Gynecol 2010; 202:599.e1.
  55. Malinger G, Lev D, Zahalka N, et al. Fetal cytomegalovirus infection of the brain: the spectrum of sonographic findings. AJNR Am J Neuroradiol 2003; 24:28.
  56. Picone O, Teissier N, Cordier AG, et al. Detailed in utero ultrasound description of 30 cases of congenital cytomegalovirus infection. Prenat Diagn 2014; 34:518.
  57. Graham D, Guidi SM, Sanders RC. Sonographic features of in utero periventricular calcification due to cytomegalovirus infection. J Ultrasound Med 1982; 1:171.
  58. Ghidini A, Sirtori M, Vergani P, et al. Fetal intracranial calcifications. Am J Obstet Gynecol 1989; 160:86.
  59. Fakhry J, Khoury A. Fetal intracranial calcifications. The importance of periventricular hyperechoic foci without shadowing. J Ultrasound Med 1991; 10:51.
  60. Estroff JA, Parad RB, Teele RL, Benacerraf BR. Echogenic vessels in the fetal thalami and basal ganglia associated with cytomegalovirus infection. J Ultrasound Med 1992; 11:686.
  61. Teele RL, Hernanz-Schulman M, Sotrel A. Echogenic vasculature in the basal ganglia of neonates: a sonographic sign of vasculopathy. Radiology 1988; 169:423.
  62. Mittelmann-Handwerker S, Pardes JG, Post RC, et al. Fetal ventriculomegaly and brain atrophy in a woman with intrauterine cytomegalovirus infection. A case report. J Reprod Med 1986; 31:1061.
  63. Ceballos R, Ch'ien LT, Whitley RJ, Brans YW. Cerebellar hypoplasia in an infant with congenital cytomegalovirus infection. Pediatrics 1976; 57:155.
  64. Shackelford GD, Fulling KH, Glasier CM. Cysts of the subependymal germinal matrix: sonographic demonstration with pathologic correlation. Radiology 1983; 149:117.
  65. Butt W, Mackay RJ, de Crespigny LC, et al. Intracranial lesions of congenital cytomegalovirus infection detected by ultrasound scanning. Pediatrics 1984; 73:611.
  66. Marques Dias MJ, Harmant-van Rijckevorsel G, Landrieu P, Lyon G. Prenatal cytomegalovirus disease and cerebral microgyria: evidence for perfusion failure, not disturbance of histogenesis, as the major cause of fetal cytomegalovirus encephalopathy. Neuropediatrics 1984; 15:18.
  67. Friede RL, Mikolasek J. Postencephalitic porencephaly, hydranencephaly or polymicrogyria. A review. Acta Neuropathol 1978; 43:161.
  68. Perlman JM, Argyle C. Lethal cytomegalovirus infection in preterm infants: clinical, radiological, and neuropathological findings. Ann Neurol 1992; 31:64.
  69. Drose JA, Dennis MA, Thickman D. Infection in utero: US findings in 19 cases. Radiology 1991; 178:369.
  70. Twickler DM, Perlman J, Maberry MC. Congenital cytomegalovirus infection presenting as cerebral ventriculomegaly on antenatal sonography. Am J Perinatol 1993; 10:404.
  71. Malinger, G, Lev, D, Zahalka, N, Ben Aroia, Z, et al. Fetal cytomegalovirus infection of the brain: the spectrum of sonographic findings. AJNR Am J Neuroradiol 24:128.
  72. Enders G, Bäder U, Lindemann L, et al. Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome. Prenat Diagn 2001; 21:362.
  73. Lipitz S, Hoffmann C, Feldman B, et al. Value of prenatal ultrasound and magnetic resonance imaging in assessment of congenital primary cytomegalovirus infection. Ultrasound Obstet Gynecol 2010; 36:709.
  74. Guerra B, Simonazzi G, Puccetti C, et al. Ultrasound prediction of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol 2008; 198:380.e1.
  75. Leyder M, Vorsselmans A, Done E, et al. Primary maternal cytomegalovirus infections: accuracy of fetal ultrasound for predicting sequelae in offspring. Am J Obstet Gynecol 2016; 215:638.e1.
  76. Bilavsky E, Yarden-Bilavsky H, Waisman Y, Marcus N. Bilateral primary spontaneous pneumothorax: buffalo chest. Pediatr Emerg Care 2009; 25:33.
  77. Lazzarotto T, Varani S, Guerra B, et al. Prenatal indicators of congenital cytomegalovirus infection. J Pediatr 2000; 137:90.
  78. Revello MG, Zavattoni M, Furione M, et al. Quantification of human cytomegalovirus DNA in amniotic fluid of mothers of congenitally infected fetuses. J Clin Microbiol 1999; 37:3350.
  79. Leruez-Ville M, Stirnemann J, Sellier Y, et al. Feasibility of predicting the outcome of fetal infection with cytomegalovirus at the time of prenatal diagnosis. Am J Obstet Gynecol 2016; 215:342.e1.
  80. Fabbri E, Revello MG, Furione M, et al. Prognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood. BJOG 2011; 118:448.
  81. Romanelli RM, Magny JF, Jacquemard F. Prognostic markers of symptomatic congenital cytomegalovirus infection. Braz J Infect Dis 2008; 12:38.
  82. Benoist G, Salomon LJ, Mohlo M, et al. Cytomegalovirus-related fetal brain lesions: comparison between targeted ultrasound examination and magnetic resonance imaging. Ultrasound Obstet Gynecol 2008; 32:900.
  83. Picone O, Simon I, Benachi A, et al. Comparison between ultrasound and magnetic resonance imaging in assessment of fetal cytomegalovirus infection. Prenat Diagn 2008; 28:753.
  84. Doneda C, Parazzini C, Righini A, et al. Early cerebral lesions in cytomegalovirus infection: prenatal MR imaging. Radiology 2010; 255:613.
  85. Farkas N, Hoffmann C, Ben-Sira L, et al. Does normal fetal brain ultrasound predict normal neurodevelopmental outcome in congenital cytomegalovirus infection? Prenat Diagn 2011; 31:360.
  86. Cahill AG, Odibo AO, Stamilio DM, Macones GA. Screening and treating for primary cytomegalovirus infection in pregnancy: where do we stand? A decision-analytic and economic analysis. Am J Obstet Gynecol 2009; 201:466.e1.
  87. Walker SP, Palma-Dias R, Wood EM, et al. Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy Childbirth 2013; 13:96.
  88. American College of Obstetricians and Gynecologists. Practice bulletin no. 151: Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. Obstet Gynecol 2015; 125:1510.
  89. Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial. Pediatr Infect Dis J 1996; 15:240.
  90. Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J Pediatr 2004; 145:485.
  91. Revello MG, Tibaldi C, Masuelli G, et al. Prevention of Primary Cytomegalovirus Infection in Pregnancy. EBioMedicine 2015; 2:1205.
  92. Revello MG, Zavattoni M, Furione M, et al. Preconceptional primary human cytomegalovirus infection and risk of congenital infection. J Infect Dis 2006; 193:783.
  93. Jacquemard F, Yamamoto M, Costa JM, et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG 2007; 114:1113.
  94. Leruez-Ville M, Ghout I, Bussières L, et al. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Am J Obstet Gynecol 2016; 215:462.e1.
  95. Nigro G, Adler SP, La Torre R, et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005; 353:1350.
  96. Nigro G, Adler SP, Parruti G, et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy--a case-control study of the outcome in children. J Infect Dis 2012; 205:215.
  97. Visentin S, Manara R, Milanese L, et al. Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis 2012; 55:497.
  98. Revello MG, Lazzarotto T, Guerra B, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 2014; 370:1316.
  99. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009; 360:1191.
  100. Dekker CL, Arvin AM. One step closer to a CMV vaccine. N Engl J Med 2009; 360:1250.
  101. Dasari V, Smith C, Zhong J, et al. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. J Gen Virol 2011; 92:1021.
  102. Sabbaj S, Pass RF, Goepfert PA, Pichon S. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis 2011; 203:1534.